Navigation Links
Viral Enzyme Recruited in Fight Against Ear Infection

St. Jude Study Success in Using Virus Enzyme to Treat Mouse Model of Acute Otitis Media Suggests that Nasal Spray Could Be Used to Prevent Both Ear Infection and Pneumonia in People with Influenza

MEMPHIS, Tenn., March 22, 2007 /PRNewswire/ -- Parents might one day give their children a weekly treatment with a nasal spray of virus enzymes to prevent them from getting a severe middle ear infection, based on results of a study done in mice by investigators from St. Jude Children's Research Hospital and The Rockefeller University, in New York. Such a treatment would avoid the use of antibiotics, thus eliminating the problem of antibiotic resistance. A report on this study appears in the March issue of the online journal "PLoS Pathogens."

Middle ear infection, also called acute otitis media, is an inflammation of the middle ear space. About half of all children carry Streptococcus pneumoniae, the bacteria that cause acute otitis media. These bacteria migrate from the nose and throat to the middle ear after an initial influenza virus infection paves the way.

The investigators based their treatment on the ability of viruses called phages to break out of bacteria they infect by using a special enzyme to destroy the cell walls.

The success of the new treatment, which uses a phage enzyme called lysin to kill S. pneumonia, suggests that the strategy could significantly reduce the incidence of acute otitis media in the United States. More than 24 million cases are now diagnosed each year, despite the use of vaccines against S. pneumoniae.

"Lysin also appears to hold promise for preventing the secondary pneumonia caused when a person infected with S. pneumoniae is subsequently infected with the influenza virus, said Jonathan McCullers, M.D., associate member in the Infectious Diseases department at St. Jude. McCullers is first author of the "PLoS" paper.

The investigators demonstrated tha t lysin can eliminate these bacteria from the ear using mice developed at St. Jude that represented the first such model in which acute otitis media develops in a similar way that it develops the disease in children. The mice were treated by purified lysin that was prepared in the laboratory of Vincent A. Fischetti, Ph.D., a professor and co- head of the Laboratory of Bacterial Pathogenesis and Immunology at The Rockefeller University. He was assisted by Jutta M. Loeffler, postdoctoral associate. Fischetti is senior author of the "PLoS" paper.

"The nasal spray may eventually be used weekly during flu season to keep a person free of Streptococcus pneumoniae or after infection with the flu virus," said Fischetti. "This might truly be a case in which an ounce of prevention would be worth a pound of cure."

Other St. Jude authors of this paper include Asa Karlstrom and Amy R. Iverson (St. Jude).

This work was supported in part by the United States Public Health Service and ALSAC.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit www.stjude.org.

CONTACT: Carrie Strehlau, St. Jude Public Relations, +1-901-495-2295,; Summer Freeman, St. Jude Public Relations,+1-901-495-3061, , or Marc Kusinitz, Ph.D.,Scientific Communications, +1-901-495-5020, carrie.strehlau@stjude.org summer.freeman@stjude.org marc.kusinitz@stjude.org

Web site: http://www.stjude.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
2. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
3. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
4. Afid Therapeutics Obtains Positive Evaluation of its Triple Mode Viral Sequestration Agents
5. NIEHS Researchers Identify Enzyme Critical in DNA Replication
6. AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV Irradiated Skin Cells
7. Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2 Predicts Heart Disease Risk in Metabolic Syndrome Patients
8. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
9. New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV
10. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
11. Alzheimers Drug Shows Promise in Fighting Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 9, 2016 Mast Therapeutics, Inc. (NYSE ... sickle cell disease and heart failure, today announced that it ... purchase common stock in an underwritten public offering.  The offering ... be no assurance as to whether or when the offering ... terms of the offering.   --> ...
(Date:2/9/2016)... Feb. 9, 2016 The new report "Global Diagnostic Ultrasound ... & Consulting group reveals that global diagnostic ultrasound devices market was ... to US$ 7,466.3 million by 2019 at a CAGR of 6.8% ... global ultrasound market has been analyzed for six geographies of ... Asia-Pacific , Latin America , ...
(Date:2/9/2016)... , Feb. 9, 2016 The leader ... that AcceleDent ® is the recipient of the ... category. An FDA-cleared, Class II medical device that speeds ... percent and relieves pain often associated with treatment, AcceleDent ... participated in the annual Orthotown survey of ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... METTLER TOLEDO has ... personnel have a basic understanding of the techniques they use so they can ... help them reduce waste and rework to create a leaner overall lab experience. ...
(Date:2/9/2016)... ... 09, 2016 , ... United Methodist Communications collaborated with Chocolate ... animated video designed to prevent the next widespread Ebola outbreak from ... being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and other African ...
(Date:2/9/2016)... ... 09, 2016 , ... Shark Finds and Kevin Harrington, and the Product Managers of ... GRIP-DRY is a newly patented product that has solved some of the basic problems golfers ... early morning dew or right after a rain shower, might understand the struggle of placing ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Federal ... federallabs.org . The site houses a wealth of federal resources that businesses ... the process called technology transfer (T2). As a network of over 300 federal ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... Houma, LA, celebrates the beginning of a new charity campaign. As part of ... Appointed Special Advocates (CASA). In the belief that children deserve a voice, and ...
Breaking Medicine News(10 mins):